APG Asset Management US’s Regeneron Pharmaceuticals REGN Stock Holding History

APG Asset Management US’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-2,240	Closed	-$1.34M	–	153
2025 Q3	$1.34M	Hold	2,240	–	–	0.01%	122
2025 Q2	$1.2M	Hold	2,240	–	–	0.01%	120
2025 Q1	$1.38M	Hold	2,240	–	–	0.01%	116
2024 Q4	$1.6M	Sell	2,240 -267	-11%	-$224K	0.01%	105
2024 Q3	$2.62M	Sell	2,507 -28,869	-92%	-$32.1M	0.02%	87
2024 Q2	$33.2M	Buy	31,376 +737	+2%	+$714K	0.19%	66
2024 Q1	$29.7M	Buy	30,639 +9,714	+46%	+$9.24M	0.17%	69
2023 Q4	$18.4M	Buy	+20,925	New	+$17.2M	0.11%	74

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

APG Asset Management US's REGN Position: Q4 2025 in Review

APG Asset Management US sold out of Regeneron Pharmaceuticals (REGN) in Q4 2025, closing a stake of 2,240 shares — an estimated $1.34M sold.

APG Asset Management US first reported a position in REGN in Q4 2023 and held it in 8 quarters. The position peaked at $33.2M in Q2 2024. 1,388 funds tracked by Wall St. Rank hold REGN as of Q4 2025.

APG Asset Management US reported no remaining Regeneron Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
APG Asset Management US sold 2,240 Regeneron Pharmaceuticals shares in Q4 2025, an estimated $1.34M.
APG Asset Management US first reported a position in Regeneron Pharmaceuticals in Q4 2023 and held it in 8 quarters.
APG Asset Management US's Regeneron Pharmaceuticals position peaked at $33.2M in Q2 2024.
1,388 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2025.

Based on APG Asset Management US's 13F filing for Q4 2025, filed 12 Feb 2026.